{"SPADE_UN_18874": {"Clinical Information": [], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_UN_18874", "Peptide Name": "Api88/Api137 (Synthetic AMPs, Pro-rich, PrAMPs, XXA, UCLL1c; Derivatives: Api134; Api137; Api155; Api161; Api162)", "Source": "Amino acid substitution, insect pro-rich peptide analog, ainmal-derived, natural derivatives", "Family": "Not found", "Gene": "Not found", "Sequence": "KNNRPVYIPRPRPPHPRL", "Sequence Length": 18, "UniProt Entry": "Ref", "Protein Existence": "Not found", "Biological Activity": ["Anti-Gram-"], "Target Organism": "Not found", "Hemolytic Activity": "Not found", "Cytotoxicity": "Not found", "Binding Target": "Not found", "Linear/Cyclic": "Not found", "N-terminal Modification": "Not found", "C-terminal Modification": "Not found", "Stereochemistry": "Not found", "Structure Description": "Not found", "Formula": "Not found", "Mass": 2207.59, "PI": 12.0, "Hydrophobicity": -1.69, "Half Life": "Not found", "Function": "Not found", "Literature": [{"Author": "Berthold N, Czihal P, Fritsche S, Sauer U, Schiffer G, Knappe D, Alber G, Hoffmann R. 2013", "Reference": "Antimicrob Agents Chemother. 2013 Jan;57(1):402-9. doi: 10.1128/AAC.01923-12.PubMed", "Title": "Novel apidaecin 1b analogs with superior serum stabilities for treatment of infections by gram-negative pathogens."}], "Frequent Amino Acids": "PRN", "Absent Amino Acids": "ACDEFGMOQSTUW", "Basic Residues": 6, "Acidic Residues": 0, "Hydrophobic Residues": 10, "Polar Residues": 10, "Positive Residues": 6, "Negative Residues": 0, "Net Charge": 6, "Comments": "Sequence analysis: APD analysis reveals that this sequence is similar (88.89%) toApidaecin IBP:33%; R: 22%; N: 11%.Chemical modification: N-terminal coupled with N,N,N=,N=-tetramethylguanidino group (Gu); warning: N-terminal ornithine is represented as K; C-terminal amidation.Activity:  active against E. coli BL21 AI (MIC 0.5 ug/ml).Half-life in vitro:serum:mouse: half life in serum(25%): 10 min; undiluted mouse serum: 5 min.SAR: Api137: the peptide without C-terminal amidation showed the same MIC against E. coli BL21 (MIC 0.5 ug/ml).In vivo PK:mice:IP: half-life 33.8 min injected at 5 mg/kg and 16.9 min injected at 20 mg/kg, longer than Api88 (11.1-17.1 min) (Schmidt et al., 2017).  IV injection 20 mg/kg: highest plasma conc at 23 mg/L with t1/2 < 30 min. However, s.c. infusion over 1 h at 19.2 mg/kg/h led to stable plasma level of ~6 mg/L, which is above MIC (?).APi134: A change of the R close to the C-end to ornithine led to Api134 with sligtly reduced activity (MIC 2 ug/ml).APi155: A change of the same R to homoR had the MIC of 2 ug/ml.Api161: attaching a C3H7 group to C-terminal amide of Api88 (MIC 4 ug/ml);Api162: attaching a CH3 group to C-terminal amide of Api88 (MIC 4 ug/ml);", "Similar Sequences": [{"SPADE_ID": "SPADE_UN_18875", "Similarity": 1.0, "Sequence": "KNNRPVYIPRPRPPHPR"}, {"SPADE_ID": "SPADE_N_08866", "Similarity": 1.0, "Sequence": "NNRPVYIPRPRPPHPRL"}, {"SPADE_ID": "SPADE_N_09118", "Similarity": 1.0, "Sequence": "NNRPVYIPPRPPHPRL"}]}}}